Catalent Pharma Solutions Expands Controlled Release Drug Development and Supply Capabilities at Its Schorndorf, Germany Facilit

Catalent Pharma Solutions Expands Controlled Release Drug Development and Supply Capabilities at Its Schorndorf, Germany Facility

1/25/2012

Somerset, NJ -January 25, 2012 - Catalent Pharma Solutions continues to expand its drug development and delivery capabilities to help customers bring better treatments to patients through innovative controlled release technologies with the announcement of significant investments at its Schorndorf, Germany facility. Highlights of this expansion include the addition of R&D and commercial scale fluid bed technology, OptiMeltTM hot melt extrusion and elevated cGMP compliance for handling of OEB class 3 customer products.

With these expanded capabilities, Catalent Schorndorf is now even better positioned to deliver customers with solutions for their most difficult bioavailability, controlled release or targeted delivery profile challenges. "This expansion follows recent investments in OSDrC® OPTIDOSETM optimized controlled release dose delivery technology at our Winchester, Kentucky site in the US, and Lyopan® fast-dissolve lyophilized tablet technology, representing Catalent's commitment to continue innovating and furthering it's position as the industry's leading global partner in oral drug delivery technologies," stated Dr. Ian Muir, President of Catalent's Modified Release Technologies business.

To learn more about Catalent's Modified Release technologies, go to:

http://www.catalent.com/index.php#delivery/mrt/controlled-release

About Catalent

From drug and biologic development services to delivery technologies to supply solutions, Catalent Pharma Solutions has the deepest expertise, the broadest offerings and the most unique technologies in the industry. With over 75 years of experience, Catalent helps customers get more molecules to market faster, enhance product performance, and provide superior, reliable manufacturing and packaging solutions. Catalent employs more than 8,000 people at 20+ facilities worldwide and in fiscal year 2011 generated more than $1.6 billion in annual revenue. Catalent is headquartered in Somerset, NJ.

more products. better treatments. reliably supplied.TM

OSDrC® is a registered trademark of Sanwa Kagaku Kenkyusho Co., Ltd

Lyopan® is a registered trademark of Pantec AG

OPTIDOSETM and OptiMeltTM are trademarks of Catalent Pharma Solutions

Media Contacts:

Patricia McGee

+1 (732) 537 6407

[email protected]

Chris Halling

+44 (0)7580 041073

[email protected]

 

Suggested Articles

After Purdue’s record opioid settlement, more deals could be on the way. But that doesn’t mean all defendants are prepared to go quietly.

Now in their third quarter on the market, Gilead's own Epclusa and Harvoni generics have together grabbed more than 20% of the U.S. hep C market.

Purdue is seeking bankruptcy after inking a $10 billion-plus opioid settlement with thousands of cities and counties, plus two dozen states.